People living with human immunodeficiency virus (HIV) have a higher risk of sudden cardiac death than people who do not have HIV, especially if the virus is not well-controlled or if they have other heart disease risk factors, ...
Sep 8, 2021
0
55
A large, detailed look at patients taking HIV-prevention drug therapy finds strong adherence soon after patients get the prescription, but less consistent use thereafter, particularly among groups considered high priority ...
Aug 26, 2021
0
0
(HealthDay)—Tuberculosis preventive treatment completion is higher with three months of rifapentine-isoniazid than six months of isoniazid among patients with HIV receiving antiretroviral therapy, according to a study published ...
Aug 24, 2021
0
37
Adolescent girls in sub-Saharan Africa are vulnerable to early unintended pregnancy, HIV, child marriage, sexual violence, female genital mutilation, and related mortality and disabilities. This is particularly the case for ...
Aug 23, 2021
0
135
More than one-third of U.S. adults with HIV are not virally suppressed. People who are not virally suppressed have lower engagement with HIV care and report more barriers to care, reports a study in the September/October ...
Aug 18, 2021
0
236
For decades, human immunodeficiency virus (HIV) infections and acquired immunodeficiency syndrome (AIDS) have been a serious health concern globally. Despite various global initiatives to control the spread and clinical advances, ...
Aug 17, 2021
0
121
(HealthDay)—For men who have sex with men (MSM) and transgender women, long-acting injectable cabotegravir (CAB-LA, an integrase strand-transfer inhibitor [INSTI]) is superior to tenofovir disoproxil fumarate-emtricitabine ...
Aug 12, 2021
0
143
When the antiretroviral regimen known as pre-exposure prophylaxis, or PrEP, was launched nearly a decade ago, patients were suddenly able to achieve near-complete protection against contracting HIV by taking just one pill ...
Aug 12, 2021
0
6
States with low initial use of HIV-prevention drugs are continuing to fall behind in usage among people at risk for the disease, a new study finds.
Aug 12, 2021
0
50
With a significantly costlier medication for HIV preexposure prophylaxis (PrEP) approved in 2019, a new study examined reasons patients switched to the new drug. Study results indicate that a minority of those who switched ...
Aug 5, 2021
0
2
